F Dx Advisors, Inc. Veracyte, Inc. Transaction History

F Dx Advisors, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 17, 2023	BUY	$20.96 - $26.99 $179,962 - $231,736	8,586 New	8,586 $218,000
Q2 2022 Aug 03, 2022	SELL	$15.45 - $29.52 $135,403 - $258,713	-8,764 Closed	0 $0
Q1 2022 May 03, 2022	BUY	$21.94 - $42.51 $62,419 - $120,940	2,845 Added 48.07%	8,764 $242,000
Q4 2021 Feb 01, 2022	BUY	$36.09 - $53.79 $50,056 - $74,606	1,387 Added 30.6%	5,919 $244,000
Q1 2020 May 13, 2020	BUY	$16.13 - $30.17 $73,101 - $136,730	4,532 New	4,532 $632,000

311

82M

134K

13.3K

Ticker VCYT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,575,904
Market Cap $3.14B
Description
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...

Get notified when there are updates to the investment portfolio of F Dx Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on F Dx Advisors, Inc. with notifications on news.